Adjuvant rituximab therapy of pemphigus a single-center experience with 31 patients

Archives of Dermatology

Volumn 148, Issue 9, 2012, Pages 1031-1036

  Lunardon, Luisa ^a   Tsai, Kathleen J ^a   Propert, Kathleen J ^a   Fett, Nicole ^a,b   Stanley, John R ^a   Werth, Victoria P ^a,b   Tsai, Donald E ^a   Payne, Aimee S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BACTERIUM ANTIBODY; CORTICOSTEROID; DESMOGLEIN ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ADJUVANT THERAPY; ADULT; AGED; ANTIBIOTIC THERAPY; ANTIBODY BLOOD LEVEL; ARTICLE; AVASCULAR NECROSIS; BLISTER; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAPELVIS ABSCESS; LUNG EMBOLISM; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; OSTEOMYELITIS; PELVIS ABSCESS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PHARYNGITIS; PHLEGMON; PRIORITY JOURNAL; PROSTATE CANCER; PSYCHOSIS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SINUSITIS; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYNCOPE; SYSTEMIC THERAPY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PEMPHIGUS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84866517889     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2012.1522     Document Type: Article

References (17)

1. Payne AS, Stanley JR. Pemphigus. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest B, Paller AS, Leffell DJ, eds. Dermatology in General Medicine. 8th ed. New York, NY: McGraw Hill; 2012.
2. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(6):545-552.
3. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355(17):1772-1779.
4. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. Arch Dermatol. 2007;143(8):1033-1038.
5. Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011;165(3):646-651.
6. Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011;65(3):552-558.
7. Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007;156(2):352-356.
8. Goh MS, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients. Br J Dermatol. 2007;156(5):990-996.
9. Feldman RJ, Ahmed AR. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses. Expert Rev Clin Immunol. 2011;7(4):529-541.
10. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043-1046.
11. Cheng SW, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol. 2002;147(2):261-265.
12. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol. 2006;142(11):1447-1454.
13. Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol. 2010;130(8):2041-2048.
14. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57(4):622-628.
15. Mouquet H, Musette P, Gougeon ML, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol. 2008;128(12):2859-2869.
16. Nagel A, Podstawa E, Eickmann M, Müller HH, Hertl M, Eming R. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol. 2009;129(9):2202-2210.
17. Amagai M. Pemphigus. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. 2nd ed. Barcelona, Spain: Mosby Elsevier; 2008.